Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2020-11-03 4:39 pm Sale | 13G | BIOLINERX LTD SPONSORED ADR NE BLRX | BIOTECHNOLOGY VALUE FUND L P | 5,946,840 1.9% | -25,295,625 (-80.97%) | View |
2020-10-20 08:59 am Purchase | 13G | CONTRAFECT CORP COM CFRX | BIOTECHNOLOGY VALUE FUND L P | 2,908,913 9.99% | 2,908,913 (New Position) | View |
2020-10-13 5:18 pm Sale | 13D | PHAXIAM THERAPEUTICS S.A. AMER PHXM | BIOTECHNOLOGY VALUE FUND L P | 4,461,941 23.5% | -85,721 (-1.88%) | View |
2020-10-09 5:20 pm Unchanged | 13D | XOMA CORP COM XOMA | BIOTECHNOLOGY VALUE FUND L P | 4,182,243 38% | 0 (Unchanged) | View |
2020-10-08 5:26 pm Purchase | 13D | FIVE PRIME THERAPEUTICS INC FPRX | BIOTECHNOLOGY VALUE FUND L P | 8,364,353 22.8% | 581,352 (+7.47%) | View |
2020-10-05 5:26 pm Purchase | 13G | NOVUS THERAPEUTICS INC NVUS | BIOTECHNOLOGY VALUE FUND L P | 195,326 15.6% | 195,326 (New Position) | View |
2020-09-23 5:28 pm Purchase | 13D | XOMA CORP COM XOMA | BIOTECHNOLOGY VALUE FUND L P | 4,182,243 38% | 156,086 (+3.88%) | View |
2020-08-25 5:27 pm Purchase | 13D | KYMERA THERAPEUTICS INC KYMR | BIOTECHNOLOGY VALUE FUND L P | 2,630,662 5.9% | 2,630,662 (New Position) | View |
2020-08-25 12:32 pm Unchanged | 13D | PRINCIPIA BIOPHARMA INC PRNB | BIOTECHNOLOGY VALUE FUND L P | 5,231,900 15.7% | 0 (Unchanged) | View |
2020-08-19 1:49 pm Purchase | 13G | PRINCIPIA BIOPHARMA INC PRNB | BIOTECHNOLOGY VALUE FUND L P | 5,231,900 15.7% | 3,515,166 (+204.76%) | View |
2020-07-20 4:35 pm Purchase | 13G | THERAPEUTICS ACQUISITION CORP RACA | BIOTECHNOLOGY VALUE FUND L P | 1,000,000 5.9% | 1,000,000 (New Position) | View |
2020-07-20 4:22 pm Purchase | 13D | INVENTIVA SA ADR IVA | BIOTECHNOLOGY VALUE FUND L P | 7,958,138 20.7% | 7,958,138 (New Position) | View |
2020-07-16 5:11 pm Purchase | 13G | UNUM THERAPEUTICS INC UMRX | BIOTECHNOLOGY VALUE FUND L P | 4,154,000 9.99% | 4,154,000 (New Position) | View |
2020-06-29 6:25 pm Purchase | 13G | REPARE THERAPEUTICS INC RPTX | BIOTECHNOLOGY VALUE FUND L P | 1,944,546 5.3% | 1,944,546 (New Position) | View |
2020-06-26 5:28 pm Purchase | 13G | CELLDEX THERAPEUTICS INC C CLDX | BIOTECHNOLOGY VALUE FUND L P | 2,740,000 7.2% | 2,740,000 (New Position) | View |
2020-06-25 5:13 pm Purchase | 13G | FORTE BIOSCIENCES FBRX | BIOTECHNOLOGY VALUE FUND L P | 1,089,983 9.99% | 1,089,983 (New Position) | View |
2020-06-22 5:23 pm Purchase | 13G | IDEAYA BIOSCIENCES INC IDYA | BIOTECHNOLOGY VALUE FUND L P | 3,224,172 11% | 1,787,743 (+124.46%) | View |
2020-06-22 5:17 pm Purchase | 13G | XENON PHARMACEUTICALS INC XENE | BIOTECHNOLOGY VALUE FUND L P | 3,516,851 10.1% | 860,794 (+32.41%) | View |
2020-06-22 4:36 pm Purchase | 13G | CURIS INC CRIS | BIOTECHNOLOGY VALUE FUND L P | 3,650,000 7.2% | 3,650,000 (New Position) | View |
2020-06-08 10:27 am Purchase | 13G | CALLIDITAS THERAPEUTICS AB SPO CALT | BIOTECHNOLOGY VALUE FUND L P | 4,781,562 9.7% | 4,781,562 (New Position) | View |